Vagus nerve stimulation (VNS) is an FDA-approved treatment for severe, treatment-resistant depression, working by sending mild electrical pulses along the longest cranial nerve in the body to shift activity in brain regions tied to mood regulation.1PubMed Central. Vagus Nerve Stimulation (VNS) and Treatment of Depression: To the Brainstem and Beyond It is not a first-line therapy. The people who receive it have typically tried multiple antidepressants and psychotherapies without adequate relief, and the treatment comes in both surgically implanted and newer non-invasive forms, each with different evidence behind it.
How Vagus Nerve Stimulation Ended Up as a Depression Treatment
VNS was originally developed for epilepsy. During early clinical use in the 1990s, clinicians noticed something unexpected: patients with seizure disorders who received implanted stimulators reported feeling better emotionally, even when their seizure frequency barely changed. A study evaluating mood in epilepsy patients during the first six months after implantation found significant improvements on most mood scales by the three-month mark, and those gains held at six months. Crucially, nine out of eleven mood responders were not seizure responders, suggesting the mood effect was independent of seizure control.2PubMed. Vagus nerve stimulation is associated with mood improvements in epilepsy patients That finding launched a new line of research, and in July 2005 the FDA approved VNS for severe, recurrent unipolar and bipolar depression that had failed to respond to at least four adequate medication trials.3PubMed Central. Vagus Nerve Stimulation (VNS) and Treatment of Depression: To the Brainstem and Beyond
What the Nerve Does and Why Stimulating It Affects Mood
The vagus nerve is a two-way highway between the body and the brain. About 80 percent of its fibers carry information upward, from the organs to the brainstem. The cell bodies of those afferent fibers sit in a cluster called the inferior vagal ganglion, and their signals terminate mainly in the nucleus of the solitary tract, a brainstem relay station. From there, projections fan out to the locus coeruleus (the brain’s primary norepinephrine hub), the dorsal raphe nucleus (a major source of serotonin), the amygdala, the thalamus, the hypothalamus, and several other structures involved in emotion, pain, and internal body monitoring.4PubMed Central. The anatomical basis for transcutaneous auricular vagus nerve stimulation
Stimulating the vagus nerve electrically taps into this wiring. Recordings in animal models show that VNS ramps up the firing rate of norepinephrine neurons within a single day. Serotonin neurons follow about two weeks later, apparently through a cascade effect: the extra norepinephrine activates receptors on serotonin neurons, coaxing them to fire more. That delayed serotonin boost mirrors what happens with conventional antidepressants, but VNS achieves it through a different entry point, which may explain why it can help when medications have failed.5Journal of Psychiatry and Neuroscience. Enhancement of the function of rat serotonin and norepinephrine neurons by sustained vagus nerve stimulation Both norepinephrine and serotonin turn out to be necessary for VNS-driven brain plasticity; depleting either one in animal studies blocks the effect entirely.6PubMed Central. Norepinephrine and serotonin are required for vagus nerve stimulation directed cortical plasticity
Changes in Brain Activity and Structure
Brain-imaging studies in people with treatment-resistant depression show that chronic VNS reshapes activity in regions consistently linked to depressive symptoms. Over a year of stimulation, metabolism in the ventromedial prefrontal cortex, a strip running from the subgenual cingulate to the frontal pole, declined substantially. That area has dense connections to the amygdala and structures that monitor internal body states, and its overactivity is a hallmark of severe depression.7PubMed Central. Chronic vagus nerve stimulation for treatment-resistant depression decreases resting ventromedial prefrontal glucose metabolism Separately, blood-flow studies after about ten weeks of VNS found increased circulation in the left dorsolateral prefrontal cortex, a region associated with executive function and emotional regulation that tends to be underactive in depression.8PubMed. Chronic vagus nerve stimulation for treatment-resistant depression increases regional cerebral blood flow in the dorsolateral prefrontal cortex
At the cellular level, VNS appears to promote the growth of new neurons and the health of existing ones. Animal research shows that chronic stimulation boosts brain-derived neurotrophic factor (BDNF), a protein critical for neuronal survival and the formation of new connections, by more than double in the hippocampal CA3 region, with the number of BDNF-positive cells jumping by about 40 percent.9International Journal of Neuropsychopharmacology. Chronic vagus nerve stimulation induces neuronal plasticity in the rat hippocampus Conversely, cutting the vagus nerve decreases BDNF expression throughout the hippocampus and reduces the proliferation of new brain cells there.10PubMed. The vagus nerve modulates BDNF expression and neurogenesis in the hippocampus The hippocampus is often smaller in people with chronic depression, so a treatment that encourages it to rebuild is mechanistically appealing.
Inflammation and the Cholinergic Anti-Inflammatory Pathway
There is growing evidence that depression involves low-grade systemic inflammation, and the vagus nerve plays a major role in controlling that inflammation. One of its key tools is the alpha-7 nicotinic acetylcholine receptor, which mediates anti-inflammatory signaling. In rat models of chronic stress, non-invasive vagus nerve stimulation reversed depression-like behavior through a signaling pathway that depends on this receptor. When the receptor was knocked out genetically, the antidepressant-like effects of stimulation largely disappeared.11CNS Neuroscience & Therapeutics. Anti‐neuroinflammation effects of transcutaneous auricular vagus nerve stimulation against depression‐like behaviors via hypothalamic α7nAchR/JAK2/STAT3/NF‐κB pathway in rats exposed to chronic unpredictable mild stress This anti-inflammatory arm of VNS is separate from the neurotransmitter effects described earlier, giving the treatment at least two distinct routes through which it may relieve depression.
People with depression also tend to have low vagal tone, meaning the nerve is less active at baseline. Chronic stress can dampen vagal output, which may increase gut permeability and systemic inflammation, both of which feed back into depressive symptoms through what researchers call the microbiota-gut-brain axis.12PubMed Central. Recognizing the role of the vagus nerve in depression from microbiota-gut brain axis VNS, by artificially boosting vagal activity, may help break this cycle.
How Well Does Implanted VNS Work
The clinical picture for implanted VNS is unusual. Effects tend to build slowly, often over months, which makes it unlike most antidepressants or electroconvulsive therapy, where you expect a response within weeks. It is explicitly not a treatment for acute crisis.13PubMed Central. Somatic therapies for treatment-resistant depression: ECT, TMS, VNS, DBS
The largest controlled trial of VNS for treatment-resistant depression, results of which were published in 2024, found that active VNS produced a significantly higher clinician-rated response rate than a control condition. Patient self-reports also showed a modest but significant improvement. Perhaps most striking was the partial response rate: patients who experienced at least a 30 percent reduction in symptoms were significantly more common in the VNS group, suggesting meaningful clinical benefit even among those who did not reach the traditional “responder” threshold.14PubMed Central. Vagus Nerve Stimulation (VNS) and Treatment of Depression: To the Brainstem and Beyond This matters because the patients in these trials are among the hardest to treat in all of psychiatry. Even a partial improvement in someone who has been ill for years and tried everything else can translate to a meaningful change in daily functioning.
Non-Invasive Alternatives
Because surgically implanting a stimulator in someone’s chest and threading a wire to a nerve in their neck is a serious step, researchers have been developing non-invasive alternatives. The most studied is transcutaneous auricular VNS, or taVNS, which delivers electrical stimulation through the skin of the ear. A small branch of the vagus nerve innervates part of the outer ear, and stimulating that spot sends signals to the same brainstem relay areas as the implanted device.15PubMed Central. The anatomical basis for transcutaneous auricular vagus nerve stimulation
A meta-analysis pooling twelve randomized controlled trials with over 800 participants found that taVNS significantly improved depression scores. The quality of the evidence was rated low to very low, but the direction was consistent: taVNS performed better than sham stimulation and showed response rates comparable to antidepressants, with fewer side effects.16PubMed. The efficacy and safety of transcutaneous auricular vagus nerve stimulation in the treatment of depressive disorder: A systematic review and meta-analysis of randomized controlled trials A recent open-label pilot trial also found that an accelerated taVNS protocol, where patients received multiple sessions per day over a short inpatient stay, significantly reduced both depression and anxiety scores from baseline.17PubMed Central. Accelerated Transcutaneous Auricular Vagus Nerve Stimulation for Inpatient Depression and Anxiety: The iWAVE Open Label Pilot Trial
The honest assessment of non-invasive VNS right now is that it is promising but still early. The trials are small, the sham conditions are hard to blind perfectly (you can often feel the stimulation), and there is no standardized protocol for frequency, intensity, or duration. Consumer-facing ear-clip devices are already on the market, but the evidence supporting their specific configurations is thin compared to what exists for the implanted device.
Side Effects and Risks
Implanted VNS is generally well tolerated, but it is not without side effects. The most commonly reported one is voice alteration or hoarseness, which showed up in the vast majority of patients across a systematic review and meta-analysis of implanted VNS studies. Roughly a third experienced tingling sensations, about 30 percent reported pain, a similar proportion had increased cough, and around 28 percent experienced some breathing difficulty during stimulation.18Cerebrovascular Diseases. Complications of Implanted Vagus Nerve Stimulation: A Systematic Review and Meta-Analysis These effects are typically most noticeable during the 30-second “on” periods of stimulation and fade between cycles. For many patients, they diminish over weeks as the body adjusts and settings are fine-tuned.
Surgical complications are less common but worth knowing about. Infection rates after implantation run between 3 and 8 percent. Rarer events include intraoperative slowing of the heart during lead testing, vocal cord paralysis from nerve injury, and delayed issues like obstructive sleep apnea or late infections around the device.19Epilepsia. Vagus nerve stimulation: Surgical technique of implantation and revision and related morbidity An analysis of FDA adverse event reports identified over 12,000 documented vagus nerve issues after VNS implantation, with apnea being the single most commonly reported patient problem. Laryngeal effects, including voice changes and vocal cord paresis, were the eighth most common category.20PubMed Central. Laryngology Outcomes Following Implantable Vagus Nerve Stimulation
Non-invasive taVNS, by contrast, is considerably gentler. The most common complaints are mild skin irritation at the ear clip site, tingling, and occasional mild headache. Because no surgery is involved and the electrical dose is much lower, the risk profile is dramatically different.
How VNS Compares to Other Brain Stimulation Treatments
VNS sits in a landscape of neuromodulation options for depression that have not responded to medication. Electroconvulsive therapy (ECT) remains the most powerful option for acute, severe, treatment-resistant depression, with relatively rapid effects, but carries cognitive side effects that concern many patients and clinicians. Transcranial magnetic stimulation (TMS) is safe, well-tolerated, and FDA-approved for people who have failed to respond to one antidepressant, but its evidence in more entrenched depression is weaker, and its use in treatment-resistant cases remains debated.21PubMed Central. Somatic therapies for treatment-resistant depression: ECT, TMS, VNS, DBS
VNS occupies a different niche. It is not fast-acting, so it is not suited for someone in a depressive emergency. But its effects may accumulate over time, potentially making it better suited for the long game of chronic treatment-resistant depression. There is limited data in older adults specifically, though what exists suggests effectiveness in that group as well.22PubMed Central. The Efficacy and Safety of Neuromodulation Treatments in Late-Life Depression Deep brain stimulation (DBS), which involves implanting electrodes directly into specific brain targets, is the most invasive option and is still largely experimental for depression.
Device Settings and Why They Matter
An implanted VNS device is not simply switched on and left alone. It requires careful programming by a clinician, and the parameters can significantly affect both outcomes and tolerability. The electrical current typically starts low, around 0.25 milliamps, and is gradually increased to wherever the patient can comfortably tolerate it, usually somewhere between 1.0 and 1.5 milliamps, with a maximum of 3.5 milliamps. The stimulation frequency is usually set at 20 Hz for depression (compared to 30 Hz for epilepsy), and the pulse width at 250 or 500 microseconds. Higher current settings bring more side effects, especially voice changes, cough, and a tightness in the throat.23PubMed. Vagus nerve stimulation therapy in depression and epilepsy: therapeutic parameter settings
Finding the right balance is a process. Most patients cycle through 30 seconds of stimulation followed by five minutes off, around the clock. The device can be temporarily deactivated by holding a magnet over the chest, which gives patients some control during activities like public speaking or eating where voice alteration would be especially disruptive.
Predicting Who Will Respond
One of the most frustrating aspects of VNS for depression is that there is no reliable way to predict ahead of time who will benefit. However, researchers are investigating biomarkers that could help. One intriguing finding involves heart rate variability, a measure of how much the interval between heartbeats fluctuates. Because the vagus nerve directly regulates heart rhythm, people with higher baseline vagal tone (reflected in greater heart rate variability) may respond differently to stimulation. Early research suggests that a specific measure of heart rate variability could help stratify patients for non-invasive VNS treatment.24Translational Psychiatry. The heart knows best: baseline heart rate variability as guide to transcutaneous auricular vagus nerve stimulation in depression
Another potential predictor comes from the electrocardiogram. In a study of patients receiving implanted VNS, those with a longer baseline QTc interval (a measure of the heart’s electrical cycle) showed larger improvements in mood over one and two years of stimulation. The correlation was strong enough to suggest that a simple cardiac measurement taken before implantation could one day help identify better candidates.25The Journal of ECT. Electrocardiogram Corrected Q-T Interval Predicts Response to Vagus Nerve Stimulation in Depression Both of these markers reflect the state of the autonomic nervous system, which makes sense given that VNS works by modulating that system directly. But neither has been validated in large prospective trials, so they remain research tools rather than clinical decision-makers.
Cost and Insurance Coverage
Implanted VNS is expensive. The device itself costs tens of thousands of dollars, surgery adds to that, and the battery needs replacement every several years. In the United States, insurance coverage is inconsistent. The FDA approval for depression came under a “humanitarian device exemption” rather than through the standard premarket approval process, which has made some insurers reluctant to cover it. Many patients and their psychiatrists spend considerable time navigating prior authorization requirements.
A cost-effectiveness analysis modeled in the UK found that VNS generated about 0.42 additional quality-adjusted life years compared to treatment as usual, at an incremental cost of roughly £30,000 per quality-adjusted life year gained when only direct medical costs were counted. When societal costs were included, such as lost productivity and caregiver burden, VNS actually became the less expensive option overall. Extending the analysis to a 20-year horizon further improved the ratio.26Value in Health. Cost-Effectiveness of Vagus Nerve Stimulation for Treatment-Resistant Depression in the United Kingdom The economic argument for VNS leans heavily on the idea that severe treatment-resistant depression is extraordinarily costly on its own: frequent hospitalizations, disability, emergency visits, and years of ineffective medication trials add up.
The Gut-Brain Connection
One of the more fascinating research directions involves the vagus nerve’s role as the primary communication cable between the gut and the brain. The nerve’s afferent fibers can sense signals from gut bacteria and relay them upward, while its efferent fibers carry brain signals back down to modulate gut inflammation and permeability.27PubMed Central. Recognizing the role of the vagus nerve in depression from microbiota-gut brain axis Chronic stress can suppress vagal output, which may allow the gut lining to become leaky and inflammatory molecules to escape into the bloodstream, ultimately reaching the brain. This loop is bidirectional: brain inflammation can worsen gut problems, and gut inflammation can worsen depression.
VNS, by artificially activating the nerve, may help on both ends of this loop simultaneously, calming brain circuits involved in mood while also tamping down peripheral inflammation through the cholinergic anti-inflammatory pathway. Whether this gut-mediated mechanism contributes meaningfully to VNS’s clinical antidepressant effect in humans, or is primarily an interesting parallel finding from animal research, remains to be worked out. But it does help explain why some researchers are exploring VNS for conditions beyond depression and epilepsy, including inflammatory bowel disease and rheumatoid arthritis, where vagal anti-inflammatory signaling could play a therapeutic role.